Thrombocytopenia following chemotherapy in paediatric oncology
Conditions
Interventions
Romiplostim (N01) intervention group:Administration of Ropastin N01
Sponsors
The First Affiliated Hospital,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.0 years old = 1.5×10^9 /L, PLT >= 80×10^9 /L, Hb >= 75g/L, WBC >= 3.0×10^9 /L); 7. Receiving high intensity chemotherapy regimens such as SCCCG lymphoma regimen, CAV/IE, VIP regimen, etc., with an expected degree II or greater myelosuppression after chemotherapy. 8. The legal guardian of the subject must sign the informed consent form. Translated with DeepL.com (free version)
Exclusion criteria
Exclusion criteria: 1.Poorly controlled systemic infection. 2.Severe dysfunction of vital organs. 3.Participation in any clinical trial involving Nplate (Romiplostim) N01 or similar pharmaceuticals within 4 weeks prior to enrollment. 4.Known hypersensitivity to Nplate (Romiplostim) N01. 5.Severe psychiatric disorder that may compromise the provision of informed consent and/or the reporting or observation of adverse reactions. 6.Patients deemed by the investigator to be otherwise unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with platelet count<50 × 10 ^9 /L during the prophylactic treatment period of Lopsetin N01; | — |
Secondary
| Measure | Time frame |
|---|---|
| PLT < 50 × 10 ^9 /L duration;The proportion and corresponding number of platelet transfusions received;incidence of treatment-related adverse reactions; | — |
Countries
China
Contacts
Public ContactYan-Lai Tang
The First Affiliated Hospital,Sun Yat-sen University
Outcome results
None listed